Vertical Nanowire TFET Diameter Influence on Intrinsic Voltage Gain for Different Inversion Conditions

In this work, the impact of the nanowire TFET diameter on analog parameters in "weak" and "strong inversion" conditions is analyzed. Its relation with the current conduction mechanism is also studied. A comparison of the analog performance among TFETs doped with different source doping profile (abrupt and nonabrupt) and MOSFETs was experimentally realized for larger diameter nanowires. Additionally the TFET evaluation was extrapolated for smaller diameters by numerical simulation. The transistor efficiency and the Early voltage were considered in order to calculate the intrinsic voltage gain (AV). Both effects influence AV degradation for TFETs with smaller diameters biased in "weak inversion". While larger TFET nanowires show better AV than MOSFETs under "strong inversion" bias, narrower nanowires present potentialities for low power and low voltage applications, since their AV is better than the corresponding values for larger diameters TFET nanowires under "weak inversion" bias

Relationship Between Risk Factors and Mortality in Type 1 Diabetic Patients in Europe: The EURODIAB Prospective Complications Study (PCS)

OBJECTIVE—The purpose of this study was to examine risk factors for mortality in patients with type 1 diabetes

Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: The EURODIAB Prospective Complications Study

Impaired regulation of extracellular matrix remodeling by matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) may contribute to vascular complications in patients with type 1 diabetes. We investigated associations between plasma MMP-1, -2, -3, -9, -10 and TIMP-1, and cardiovascular disease (CVD) or microvascular complications in type 1 diabetic patients. We also evaluated to which extent these associations could be explained by low-grade inflammation (LGI) or endothelial dysfunction (ED). Methods: 493 type 1 diabetes patients (39.5 ± 9.9 years old, 51% men) from the EURODIAB Prospective Complications Study were included. Linear regression analysis was applied to investigate differences in plasma levels of MMP-1, -2, -3, -9, -10, and TIMP-1 between patients with and without CVD, albuminuria or retinopathy. All analyses were adjusted for age, sex, duration of diabetes, Hba1c and additionally for other cardiovascular risk factors including LGI and ED. Results: Patients with CVD (n = 118) showed significantly higher levels of TIMP-1 [β = 0.32 SD (95%CI: 0.12; 0.52)], but not of MMPs, than patients without CVD (n = 375). Higher plasma levels of MMP-2, MMP-3, MMP-10 and TIMP-1 were associated with higher levels of albuminuria (p-trends were 0.028, 0.004, 0.005 and 0.001, respectively). Severity of retinopathy was significantly associated with higher levels of MMP-2 (p-trend = 0.017). These associations remained significant after further adjustment for markers of LGI and ED. Conclusions: These data support the hypothesis that impaired regulation of matrix remodeling by actions of MMP-2, -3 and-10 and TIMP-1 contributes to the pathogenesis of vascular complications in type 1 diabetes

Effects of step duration in incremental ramp protocols on peak power and maximal oxygen consumption

Purpose: Morton (J Sport Sci 29:307–309, 2011) proposed a model of the peak power attained in ramp protocol ( w˙peak ) that included critical power (CP) and anaerobic capacity as constants, and mean ramp slope (S) as variable. Our hypothesis is that w˙peak depends only on S, so that Morton’s model should be applicable in all types of ramps. The aim of this study was to test this hypothesis by validating Morton’s model using stepwise ramp tests with invariant step increment and increasing step duration. Methods: Sixteen men performed six ramp tests with 25 W increments. Step duration was: 15, 30, 60, 90, 120 and 180 s. Maximal oxygen consumption ( V˙O2max ) and w˙peak were identified as the highest values reached during each test. An Åstrand-type test was also performed. We measured oxygen consumption and ventilatory variables, together with lactate and heart rate. Results: V˙O2max was the same in all tests; w˙peak was significantly lower the longer the step duration, and all values differed from the maximal power of the Åstrand-type test ( w˙max ). Morton’s model yielded an excellent fitting, with mean CP equal to 198.08 ± 37.46 W and anaerobic capacity equal to 16.82 ± 5.69 kJ. Conclusions: Morton’s model is a good descriptor of the mechanics of ramp tests. Further developments of Morton’s model demonstrated that, whereas w˙peak is a protocol-dependent variable, the difference between w˙max and CP is a constant, so that their values do not depend on the protocol applied